SCHEMBL1503133

SCHEMBL1503133

NC(=O)c1cnc(C(=O)N(O)Cc2ccc(Cl)c(Cl)c2)c(O)c1CO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.36
RPS6KB1 P23443 4/20 0.36
CYP2C19 P33261 1/20 0.36
AURKA O14965 2/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
PIK3CA P42336 1/20 0.34
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
GFER P55789 1/20 0.33
STAT6 P42226 2/20 0.33
CD38 P28907 1/20 0.33
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1503197 0.69 HDAC1 (0.46) ALDH1A1
SCHEMBL1503063 0.67 GPR52 (0.43) RPS6KB1AURKAPIK3CAALDH1A1
SCHEMBL3443069 0.62 KDM4E (0.56) CYP2C19ALDH1A1
SCHEMBL2483572 0.61 RPS6KB1 (0.54) RPS6KB1AURKASLC6A2SLC6A4SLC6A3
SCHEMBL5549902 0.60 ADRA1D (0.52) PIK3CAHTTALDH1A1
SCHEMBL2892390 0.60 ALDH1A1 (0.47) HTTALDH1A1
SCHEMBL22283906 0.60 KDM4E (0.37) ALDH1A1
SCHEMBL10098876 0.59 TAAR1 (0.47) GBA1CYP2C19SLC6A2SLC6A4SLC6A3
SCHEMBL1503182 0.59 EGLN1 (0.36) GAAHTTALDH1A1
SCHEMBL8181562 0.58 GBA1 (0.69) GBA1SLC6A2SLC6A4SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US claimed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US claimed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP claimed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO claimed
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US disclosed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US disclosed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP disclosed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE PNPO, CCNB1, BLVRB GBA1 2679/4885RPS6KB1 1100/4885CYP2C19 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.